Background: In developed nations, bladder cancer is a main cause of mortality. Urothelial bladder cancer (UBC) makes up
the bulk of cases up to (90%) . An important lipid metabolism enzyme called LPCAT1 has been linked to the development
of various cancers. HuR is an RNA-binding protein involved in tumor growth, regulates normal cell proliferation and
inflammatory responses associated with cancer (13). that regulates the healthy cell proliferation and inflammatory responses
associated with cancer. The study aimed to evaluate the significance expression of RBM-HuR and LPCAT1 in UBC.
Methods: The current retrospective study included 50 formalin-fixed, paraffin-embedded blocks
for UBC. to examine the expression of both RBM-HuR and LPCAT in UBC was performed using Immunohistochemistry
where. anti RBM-HuR and anti LPCAT1 immunostaining were performed using Avidin-Biotin complex technique and
correlated to clinicopathological parameters including pT stage and grade of the tumor, lymph node (LN) metastasis, distant
metastasis, lympho-vascular invasion, and associated CIS
Results: LPCAT1 expression was negatively correlated with the ( pT stage and grade of the tumor, lymph node (LN)
metastasis, distant metastasis, lympho-vascular invasion, and associated CIS) (P < 0.05). However, RBM-HuR expression
was positively correlated to the same clinicopathological criteria. (P< 0.05).
Conclusions: RBM-HuR and LPCAT1 could both be used as potential prognostic indicators in UBC.